论文部分内容阅读
目的:探讨α-D_3对原发性肾病综合征(PNS)患者Pred激素治疗过程中发生骨质疏松的影响。方法:收集我院70例PNS患者,随机分为实验组和对照组。对照组给予泼尼松治疗,实验组在对照组基础上给予α维生素D_3(α-D_3)治疗。观察并比较两组患者治疗前后骨碱性磷酸酶(NBAP)、抗酒石酸酸性磷酸酶(TRACP)、1,25-(OH)_2D_3、前甲状腺素原(iPTH)及骨密度水平的变化情况。结果:与治疗前相比,治疗后两组患者1,25-(OH)_2D_3及骨密度水平均升高,差异具有统计学意义(P<0.05);与治疗前相比,治疗后两组患者NBAP,TRACP及iPTH水平均降低,差异具有统计学意义(P<0.05);与对照组比较,实验组患者治疗后1,25-(OH)_2D_3及骨密度水平较高,差异具有统计学意义(P<0.05),与对照组比较,实验组患者治疗后NBAP,TRACP及iPTH水平较低,差异具有统计学意义(P<0.05)。结论:α-D_3能够降低原发性肾病综合征患者Pred激素治疗期间NBAP,TRACP,iPTH水平,提高1,25-(OH)2D3、骨密度,从而有效预防骨质疏松。
Objective: To investigate the effect of α-D_3 on the occurrence of osteoporosis in patients with primary nephrotic syndrome (PNS) during the course of Pred Hormone Therapy. Methods: Seventy patients with PNS in our hospital were randomly divided into experimental group and control group. The control group was given prednisone, and the experimental group was given α-D_3 (α-D_3) on the basis of the control group. The changes of bone alkaline phosphatase (NBAP), tartrate-resistant acid phosphatase (TRACP), 1,25- (OH) 2D_3, prethorathyroid hormone (iPTH) and bone mineral density (BMD) before and after treatment were observed and compared between the two groups. Results: Compared with those before treatment, the levels of 1,25- (OH) 2D2 and bone mineral density in both groups increased after treatment, the difference was statistically significant (P <0.05). Compared with before treatment, the two groups The levels of NBAP, TRACP and iPTH in the patients decreased, with statistical significance (P <0.05). Compared with the control group, the levels of 1,25- (OH) _2D_3 and bone mineral density in the experimental group were higher after treatment, the difference was statistically significant (P <0.05). Compared with the control group, the levels of NBAP, TRACP and iPTH were lower in the experimental group after treatment, the difference was statistically significant (P <0.05). CONCLUSION: α-D_3 can reduce NBAP, TRACP and iPTH levels and increase 1,25- (OH) 2D3 and BMD during the course of Pred Hormone Therapy in patients with primary nephrotic syndrome, thereby effectively preventing osteoporosis.